- |||||||||| Repatha (evolocumab) / Amgen, Astellas
A CASE OF EVOLOCUMAB-INDUCED PNEUMONITIS (Convention Center Exhibit Hall: Poster Area) - Sep 11, 2022 - Abstract #CHEST2022CHEST_4036;
Other monoclonal antibodies, such as infliximab, adalimumab, certolizumab, and ustekinumab, have all been reported to cause pneumonitis in patients. Evolocumab has not been reported to cause pneumonitis, but given this presentation, negative work up for other etiologies and previous reports of monoclonal antibodies causing pneumonitis, it is postulated this patient may have developed evolocumab induced pneumonitis.
- |||||||||| Clinical, Retrospective data, Review, Journal: Efficacy and safety of biologic therapy in microscopic colitis: systematic review and meta-analysis. (Pubmed Central) - Sep 10, 2022
Low-quality evidence supports the short-term efficacy of biologics in budesonide refractory MC. While our findings represent the most comprehensive evaluation of biologic therapy in severe MC, further research including randomized clinical trials is needed to better define the role of specific agents and long-term therapy.
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date: Pediatric Arthritis Study of Certolizumab Pegol (clinicaltrials.gov) - Sep 10, 2022
P3, N=193, Active, not recruiting,
While our findings represent the most comprehensive evaluation of biologic therapy in severe MC, further research including randomized clinical trials is needed to better define the role of specific agents and long-term therapy. Trial completion date: Apr 2024 --> Dec 2024
- |||||||||| Smoking Adversely Impacts Therapeutic Response to Treatment in IBD Patients (Crown Ballroom) - Sep 4, 2022 - Abstract #ACG2022ACG_4016;
Among never-smoker IBD, Crohn’s and UC patients, those who received biologics, immunomodulators or both had a lower mean CRP/Albumin ratio than those who did not (Table 1). Never-smoker IBD and UC patients who used biologics, had statistically significant lower mean CRP/Albumin ratio than those who did not, (p=0.010 and p=0.006, respectively).
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Persistence Among Patients With Crohn’s Disease Previously Treated With an Anti-tumor Necrosis Factor Inhibitor and Switching or Cycling to Another Biologic Agent (Crown Ballroom) - Sep 4, 2022 - Abstract #ACG2022ACG_2468;
At 12 months post-index, the proportions of patients persistent to the index agent and patients persistent while on-monotherapy were significantly higher in the switching compared to the cycling cohort ( Figure 1 ). In the switching compared to the cycling cohort, the rate of being persistent to the index agent was 44% higher ( hazard ratio [HR]: 1.44; 95% confidence interval [CI]: 1.11-1.88; P =0.007*), the rate of being persistent and corticosteroid-free 8% higher (HR: 1.08; 95% CI: 0.89-1.32; P =0.426), and the rate of being persistent while on-monotherapy 56% higher (HR: 1.56; 95% CI: 1.28-1.90; P < 0.001*).
- |||||||||| Impact of Biologic Therapies on Risk of Major Adverse Cardiovascular Events in Crohn’s Disease: Systematic Review and Meta-Analysis of Randomized Controlled Trials (Crown Ballroom) - Sep 4, 2022 - Abstract #ACG2022ACG_1945;
There was no evidence of statistical heterogeneity across the studies using the I2 statistic (I2=0). Biologic therapies were not associated with increased risk of MACEs during induction [infliximab (OR 0.63, 95% CI 0.07–6.14), adalimumab (OR 0.72, 95% CI 0.07–6.96), ustekinumab (OR 0.50, 95% CI 0.03–8.04), natalizumab (OR 0.50, 95% CI 0.05–4.86), vedolizumab (OR 0.53, 95% CI 0.06–5.12), certolizumab (OR 1.90, 95% CI 0.16–22.76) and risankizumab (OR 0.34, 95% CI 0.01–17.12)].
- |||||||||| Stelara (ustekinumab) / J&J
Gradient Boosted Decision Tree to Model Ustekinumab Trough Levels in Crohn’s Disease (Crown Ballroom) - Sep 4, 2022 - Abstract #ACG2022ACG_1803;
Univariate analysis determined the following variables to be significant predictors: female gender, dosing schedule, time on UST, ESR, CRP, failed adalimumab, failed infliximab, failed certolizumab, and the Montreal classifications B1, B3, L1, L3. Results of various input variable combinations are outlined in figure 1.
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Journal: When Autoimmunity 'DRESSes up': A Case after Certolizumab Therapy. (Pubmed Central) - Sep 3, 2022
Approximately half of the CD patients were between age 35 to 54. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is an uncommon and under-reported syndrome.Its recognition is critical for treatment, especially in the emergency setting where most patients first present.In the case of unexplained fever, lymphadenopathy, cutaneous rash and characteristic laboratory findings (e.g., eosinophilia), after infectious causes have been ruled out, clinicians should always keep DRESS in mind and consider possible recent intake of a triggering drug.
- |||||||||| Efficacy of Targeted Drugs for the Treatment of Adults With Moderate-to-Severe Plaque Psoriasis in the Russian Federation: A Systematic Literature Review Update (Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_737;
Evidence synthesis included RCTs evaluating the efficacy of adalimumab (ADA), infliximab (INF), etanercept (ETN), certolizumab pegol (CZP), ixekizumab (IXE), netakimab (NTK), secukinumab (SEC), risankizumab (RIS), guselkumab (GUS), ustekinumab (UST), tofacitinib (TOFA), and apremilast (APR) after 12 weeks of therapy. The addition of head-to-head trials and increased statistical power of the network revealed previously unidentified significant differences between treatment options for moderate-to-severe plaque psoriasis.
- |||||||||| Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Five Cases of Seronegative Persistent Inflammatory Monoarthritis Improved with Biological Therapy. (Pubmed Central) - Aug 13, 2022
We investigated the usefulness of biological disease-modifying antirheumatic drugs for the treatment of seronegative persistent inflammatory monoarthritis. We obtained a remarkable improvement effect and prevented the advance of joint destruction.
- |||||||||| Review, Journal: TNF-α/Anti-TNF-α drugs and its effect on pregnancy outcomes. (Pubmed Central) - Aug 11, 2022
Moreover, we summarized the reports about the adverse pregnancy outcomes (PE, IUGR, SA and preterm birth) of using anti-TNF-α drugs (infliximab, etanercept and adalimumab, certolizumab and golimumab) currently in the clinical studies. No abstract available
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Uveitis Due To Immune-Mediated Inflammatory Diseases Treated With Certolizumab Pegol. Spanish Multicenter Study Of 80 Patients. (Screen # 1) - Aug 7, 2022 - Abstract #PANLAR2022PANLAR_338;
Previous biologic therapy was administered in 52 patients (63%): 48 adalimumab, 32 infliximab, 15 golimumab, 5 tocilizumab, 7 etanercept, 1 rituximab, 1 anakinra and 1 secukinumab...297.1±45. 286.5±39.8 277.6±43.3 271.5±38.6 269.0±38.8 1 5 * * * * Choroiditis, affected eyes, n (%) 3 (2.4) 3 (2.4) 2 (1.6) 2 (1.6) 1 (0.8) 1 (0.8) Retinal vasculitis, affected eyes, n (%) 3 (2.4) 2 (1.6) 1 (0.8) 0 (0) 0 (0) 0 (0) *p<0.01 Conclusion CZP seems to be effective and safe in the control of uveitis associated to IMIDs.
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Peripheral Spondyloarthritis As An Imitator Or Trigger Of Demyelinating Peripheral Neuropathy (Screen # 2) - Aug 7, 2022 - Abstract #PANLAR2022PANLAR_332;
Endoscopy disclosed Forrest IIb-C jejunal ulcer and esophageal candidiasis, managed with high dose omeprazole and antifungal agents...Because of gastrointestinal bleeding and dependence on corticosteroids for symptom control, we started treatment with certolizumab pegol with excellent response...Spondyloarthropathies are a heterogeneous group of musculoskeletal inflammatory diseases; they can be axial or peripheral. Polyneuropathy associated with peripheral spondyloarthritis is an uncommon clinical manifestation that should be considered in the differential diagnosis of peripheral polyneuropathies.
- |||||||||| Frequency Of Use And Annual Costs Of Biological Therapy For Psoriatic Arthritis In Colombia During 2019 (Screen # 3) - Aug 7, 2022 - Abstract #PANLAR2022PANLAR_323;
Use and cost of biological therapy in 2019 for psoriatic arthritis in Colombia B i o l o g i c a l Number agent patients of Percentag Annual e patient* cost per Total cost* annual Adalimumab 439 34.2% USD: 7,130 USD: 3,130,070 Secukinumab 309 24.1% USD: 6,825 USD: 2,108,925 Etanercept 210 16.36% USD: 6,000 USD: 1,260,000 Certolizumab 113 8.80% USD: 8,683 USD:981,179 Golimumab 103 8.0% USD: 4,532 USD:466,796 Ustekinumab 46 3.6% USD: 12,879 USD: 592,434 Infliximaba 45 3.5% USD: 1,858 USD: 83,610 Ixekizumab 18 1.4% USD: 13,683 USD: 246,294 Total: USD:8,869,308 *Assuming that the patient received treatment for one year, and applicable cases received a load dose *Average dollar value in 2019: 3,282 Colombian pesos a Average patient weight: 80 kg Image 1 Conclusion Though Colombia has a low prevalence of psoriatic arthritis, the annual cost per therapy is much lower compared to costs in other countries, a phenomenon that may be due to the regulation of high-cost drugs by the Colombian government. This is the first study describing demographics of psoriatic arthritis as well as the use and cost of biologic therapy for psoriatic arthritis in Colombia.
- |||||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Atlantoaxoid Involvement In Ankylosing Spondylitis: A Case Report And A Narrative Review Of The Literature (Screen # 2) - Aug 7, 2022 - Abstract #PANLAR2022PANLAR_310;
Finally, he was switched to certolizumab pegol, with an adequate response...Regarding management, there is no additional literature that suggests specific interventions, other than those already described for the management of AS. In our case, improvement was achieved with a change in biological therapy.
- |||||||||| Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
An Old Method For Current Challenges: Skin Test Conversion Of Purified Protein Derivative (Ppd) In Rheumatological Patients Treated With Anti-Tnf-Alfa (Screen # 1) - Aug 7, 2022 - Abstract #PANLAR2022PANLAR_192;
Concomitant use of immunomodulators (52 methotrexate, 23 leflunomide, 10 hidroxicloroquine, 3 sulfasalazine, 2 azathioprine and 1 mycophenolate mofetil) and glucocorticoids (33/62) was observed...PPD is a well known, cheap, sensitive and widely available method, suitable for LTBI diagnosis. Although sensitivity could be increased using, in addition, other LTBI detection methods such as IGRAs (interferon gamma release assays), they are usually unavailable in developing countries (1-2).
- |||||||||| Differences On Discontinuation Of Biologic Therapy Between Patients With Rheumatoid Arthritis And Ankylosing Spondylitis: Data From The Mexican Biologics Registry (Screen # 4) - Aug 7, 2022 - Abstract #PANLAR2022PANLAR_154;
Table p Rheumatoid Arthritis Ankylosing Spondylitis N=62 N=306 Female gender,n(%) Age, median (IQR) Disease duration, median(IQR) Comorbidities, n(%) Use of steroids, n(%): Use of cDMARD, n(%): Etanercept Infliximab Adalimumab Abatacept Tocilizumab Certolizumab Golimumab Tofacitinib Baricitinib Secukinumab Treatment duration, median(IQR) Cause of treatment suspension n(%) Inefficacy Adverse event Image 1 279(91) 52.7(44.9-59.7) 9.1(4.4-16.3) 144(47) 128(41.8) 260(85) 28(10) 10(4) 56 18) 59(19) 64(21) 45(15) 13(4) 10(3) 1(1) 0 14.8(9.4-25.6) 26(42) 41.2(29.5-49.7) 6.0(1.6-14.2) 17(27) 8(12.9) 44(71) 7(12) 12(19) 16(26) 0 0 22(35) 4(6) 0 0 1(2) 17.4(10.5-26.1) 77(56) 11(8) 15(65) 2(9) <0.001 <0.001 0.004 0.004 <0.001 0.008 <0.001 <0.001 0.637 Conclusion In this study we found clinical differences between patients with RA and AS that were not described before as disease duration and comorbidities. There were differences in bDMARD preferences, but we found no differences on drug discontinuation in Mexican patients with RA and AS.
- |||||||||| Descriptive And Retrospective Study Of Sars-Cov2 Infection In Patients With Systemic Autoimmune Diseases (Screen # 1) - Aug 7, 2022 - Abstract #PANLAR2022PANLAR_132;
Of the patients with steroid treatment, 7 were admitted to hospital, all with Prednisone at doses higher than 5mg...Table Table 1 Treatments in the total sample (n=101) N=102 Previous Biological DMARDs 54 patients Abatacept 11 Certolizumab 3 Adalimumab 10 Infliximab 9 Ixekizumab 1 Rituximab 11 Sarilimumab 1 Secukinumab 1 Golimumab 1 Tocilizumab 5 Previous Conventional DMARDs 44 patients Metotrexate 24 Azatioprine 3 Dolquine 4 Leflunomide 11 Mycophenolate mofetil 2 Image 1 Conclusion In our cohort, 18 patients required hospital admission of whom 16.7% required ICU...Two patients died of SARS-CoV2, one of whom had rheumatoid arthritis and the other spondyloarthritis. The most affected groups were Rheumatoid Arthritis and Spondyloarthritis in both SARS-CoV2 infection and admissions.
- |||||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
OUTCOMES OF ANTI-TNF TREATMENT IN CROHN’S DISEASE: A REAL LIFE, TERTIARY CENTER EXPERIENCE (Science Lounge) - Jul 20, 2022 - Abstract #UEGW2022UEGW_1898;
Two thirds of the patients had response to anti-TNF treatment, no significant difference was seen in between agents. Half of the patients has fistulising disease and fifty percent of them were non-responder.
- |||||||||| NN1213 / Novo Nordisk, Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date: Lipids, Inflammation, and CV Risk in RA (clinicaltrials.gov) - Jul 19, 2022
P=N/A, N=74, Active, not recruiting,
Female sex is an independent risk factor for the development of adverse effects to anti-TNF and for the discontinuation of biological drugs in CD and UC. Trial completion date: Feb 2022 --> Feb 2023
- |||||||||| Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Journal: Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis. (Pubmed Central) - Jul 13, 2022
Long-term, real-world CZP safety and effectiveness data are needed. In patients with untreated eRA, plasma levels of several chemokines correlate with disease activity at baseline but cannot predict remission after 24 weeks of treatment with methotrexate combined with prednisolone, anti‑TNF, CTLA‑4Ig or anti‑IL6R.
|
